Effects of Royal Jelly and Propolis on Metabolomic Signatures, Inflammation, and Cardiovascular Risk in Patients With Coronary Artery Disease.
Starting soon · Not applicable · Has a placebo group
Conditions studied: Coronary Artery Disease (CAD), Oxidative Stress, Inflammation
In brief
The aim of this project is to evaluate the effect of bioactive compound sources, propolis and royal jelly, on metabolomics, inflammation, and cardiovascular risk markers in participants with coronary artery disease. A longitudinal double-blind randomized clinical trial will be carried out, involving CAD participants for two months.
Key facts
- Study ID
- NCT07596992
- Run by
- Universidade Federal Fluminense
- People needed
- 50
- Starts
- 2026-05-18
- Expected to finish
- 2028-12-01
- Last updated by the study team
- 2026-05-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Both sexes
- Over 18 years of age;
- Diagnosed with Coronary Artery Disease: confirmed by coronary angiography, coronary computed tomography angiography, or functional testing with ischemic load);
- Participants who are asymptomatic or have angina limited to functional class III will be considered;
- Patients who have already undergone coronary revascularization and angioplasty may participate;
- the last acute coronary event must have occurred more than one year ago.
You may not qualify if…
- Unstable Coronary Artery Disease;
- Pre-operative coronary artery bypass grafting or awaiting elective angioplasty;
- Unstable angina;
- NYHA functional class III or higher;
- Advanced chronic kidney disease (creatinine clearance < 30 ml/min/1.73 m²);
- Individuals with autoimmune diseases.
Where it is running
- Denise mafra — Niterói, Rio de Janeiro, Brazil
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.